Targeted Nanoparticle Cancer Drug Strategy Attracts Funding

Developing a nanoparticle drug that promises to offer an alternative approach to chemotherapy with fewer side effects is a strategy that is attracting increasing interest in oncology circles. Among the many research groups worldwide involved in this field are Canadian researchers who have developed a drug-polymer conjugate that self-assembles into defined nanoparticles and, when injected, selectively accumulate in solid tumors. This promising research has attracted funding in order to set the technology along the road to eventual clinical trials.